Skip to main content

Month: March 2022

Resolutions of Ordinary General Meeting of AB “Ignitis grupė“ shareholders

The Extraordinary General Meeting of shareholders of AB “Ignitis grupė” (hereinafter – the Group), legal entity code 301844044, registered office at Laisvės ave. 10, Vilnius, held on 29 March, 2022, adopted the following resolutions: 1.       Regarding the assent to AB “Ignitis grupė” consolidated annual report for the year 2021, except for the part of the remuneration report.1.1. To assent to AB „Ignitis grupė“ consolidated annual report for the year 2021, except for the part of the remuneration report (link). 2.       Regarding the assent to the remuneration report of AB “Ignitis grupė”, as a part of the consolidated annual report of AB “Ignitis grupė” for the year 2021.        2.1. To assent to the remuneration report of AB “Ignitis grupė”, as a part of the consolidated annual report of AB “Ignitis grupė” for the year 2021 (link). 3.      ...

Continue reading

PyroGenesis Schedules 2021 Fiscal Year Financial Results and Business Update Conference Call

MONTREAL, March 29, 2022 (GLOBE NEWSWIRE) — PyroGenesis Canada Inc. (http://pyrogenesis.com) (TSX: PYR) (NASDAQ: PYR) (FRA: 8PY), a high-tech company (hereinafter referred to as the “Company” or “PyroGenesis”), that designs, develops, manufactures and commercializes advanced plasma processes and sustainable solutions which are geared to reduce greenhouse gases (GHG), today announced that it plans to host a conference call at 10:00 AM Eastern Time on Friday, April 1, 2022 to discuss the Company’s financial results for the 2021 fiscal year ended December 31, 2021, as well as the Company’s corporate progress and other developments. The conference call will be available via telephone by dialing toll free 877-800-3460 for U.S. callers or for international callers +1 615-622-8042 and by entering access code: 2253876. A webcast of the...

Continue reading

MultiChoice Accelerator Programme Celebrated at World Expo 2020, Dubai

MultiChoice Accelerator MultiChoice Accelerator Programme Celebrated at World Expo 2020, DubaiJohannesburg, March 29, 2022 (GLOBE NEWSWIRE) — Team South Africa celebrated their overall success by hosting the last National Day at the World Expo 2020 Dubai.  Expo 2020, which started in October 2021, saw almost 200 countries come together to display their offerings, while scouting networking opportunities, drawing investments, and solidifying relationships and future partnerships. The Department of Trade, Industry and Competition (dtic), together with MultiChoice as the official broadcast partner, set out to introduce the diverse economic value that South Africa has to offer. The six-month participation was closed out with a national ceremony hosted by the Honourable President Cyril Ramaphosa, followed by a high-level panel discussion...

Continue reading

Water Ways Receives a C$730,000 Third Blueberries Irrigation System Order in China

Third Chinese Blueberries Project Third Chinese Blueberries ProjectNOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, March 29, 2022 (GLOBE NEWSWIRE) — Water Ways Technologies Inc. (TSXV: WWT) (FRA: WWT) (“Water Ways” or the “Company“), a global provider of Israeli-based agriculture technology, providing water irrigation solutions to agricultural producers, announces that the Company’s Chinese subsidiary (in which the Company hold 73% interest), IRRI-AL TAL (Shanghai) Agriculture Technology Company Ltd. (“IAT Shanghai“), has received an order to install a 250,900 Square Meters (2,700,000 Square Feet) turnkey blueberries irrigation project in the People’s Republic of China. IAT Shanghai is expected to deliver and install the project during Q3...

Continue reading

Innovative MedTech To Enter Digital Payments Market

Innovative MedTech to Expand its Services BLUE ISLAND, Ill., March 29, 2022 (GLOBE NEWSWIRE) — Innovative MedTech, Inc. (the “Company”) (OTC: IMTH), a provider of health and wellness services, today announced that it is expanding its services and planning to enter the digital payments marketplace. As healthcare undergoes its greatest transformation of the modern era, it’s clear that the monolithic system in place is crying for innovation. The Company is answering the call by developing an all-in-one Super Healthcare App that caters to consumers, patients, hospitals, Seniors, and governments, with a solid platform of benefits and online banking. A Digital Healthcare Platform According to the CDC, the U.S. spent $3.6 trillion — 18 percent of its gross domestic product (GDP) — on healthcare, and consumers’ healthcare costs...

Continue reading

Pharvaris Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights

Phase 1 pharmacokinetics study demonstrates PHVS719 well tolerated with extended-release profile supporting once-daily dosingOrphan Drug Designation for PHA121 granted by FDARAPIDe-1, Phase 2 on-demand study of PHVS416 for the treatment of HAE attacks ongoing; top-line data anticipated in 4Q22CHAPTER-1, Phase 2 prophylactic study of PHVS416 for the prevention of HAE attacks trial enrolling patients; top-line data anticipated in 4Q22Executing from a strong financial position with cash and cash equivalents balance of €209.4 million as of December 31, 2021; runway expected into 1Q24ZUG, Switzerland, March 29, 2022 (GLOBE NEWSWIRE) — Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks, building on its deep-seated roots in hereditary...

Continue reading

Monte Rosa Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Business Updates

– Company on Track for Mid-year Filing of Investigational New Drug (IND) Application for Lead Candidate MRT-2359 – – Progressed NEK7 and CDK2 Molecular Glue Degrader Programs into Lead Optimization – – Year-end Cash and Cash Equivalents Expected to Provide Runway into Late 2024 – BOSTON, March 29, 2022 (GLOBE NEWSWIRE) — Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader (MGD) medicines, today reported business highlights and financial results for the fourth quarter and full year, ended December 31, 2021. “Last year was transformational for Monte Rosa as we continued to build out our world-class leadership team, expanded operations across our two sites in Boston and Basel, named MRT-2359 our development candidate for the GSPT1 program, and secured $377.6 million in funding,”...

Continue reading

Dycom Industries, Inc. Appoints Carmen M. Sabater As Director

PALM BEACH GARDENS, Fla., March 29, 2022 (GLOBE NEWSWIRE) — Dycom Industries, Inc. (NYSE: DY) today announced the appointment of Carmen M. Sabater as a director. Ms. Sabater is a Certified Public Accountant and currently serves as the Chief Financial Officer of Quirch Foods Parent, LLC (“Quirch”), a national food distribution company with a portfolio of owned brands. She has served in that role since February 2002 and has led Quirch’s integration strategy and also has experience with both human capital and technology functions. Prior to that, Ms. Sabater was the Controller of MasTec, Inc. from 1994 to 2000 and was then appointed as its Chief Financial Officer, serving in that role until January 2002. Ms. Sabater was previously at Deloitte & Touche, LLP, as an auditor and then as a Senior Manager from 1985 to 1994. She...

Continue reading

Teledyne Princeton Instruments announces new series of CCD cameras for Original Equipment Manufacturers

The LANSIS CCD cameras extend Teledyne’s spectroscopy portfolio into system integrator and OEM marketsLANSIS CCD Camera LANSIS spectroscopy cameras for OEM applicationsTRENTON, N.J., March 29, 2022 (GLOBE NEWSWIRE) — Teledyne Princeton Instruments, a Teledyne Technologies [NYSE: TDY] company, announces the release of LANSIS—a new spectroscopy detector designed specifically for original equipment manufacturers (OEM) and system integrators. LANSIS cameras represent the latest in CCD array detector technology specifically tailored to OEMs. Michael Case, product manager at Teledyne Princeton Instruments notes, “LANSIS camera development was driven by OEM requirements, and is designed to offer the highest reliability, performance, sensitivity, for easy integration into OEM platforms; and with competitive OEM pricing.” LANSIS is...

Continue reading

Gb Sciences’ Nanoparticle Encapsulation Technology Improves the Efficacy of Terpenes for Use in Our Chronic Pain Formulations as Demonstrated in New Research Article

On March 25, the University of Seville, Chaminade University, and Gb Sciences co-published the results from Gb Sciences-sponsored study in the International Journal of Pharmaceutics. Gb Sciences’ proprietary, time-released, oral nanoparticle technology improved the efficacy of cannabis-based terpenes in modulating a known pain receptor in this study.Featured Image for Gb Sciences Featured Image for Gb SciencesLAS VEGAS, March 29, 2022 (GLOBE NEWSWIRE) — Gb Sciences, Inc. (OTCQB:GBLX), a leading cannabis- and plant-inspired, biopharmaceutical research and development company, announces that their sponsored study investigating the effect of nanoparticle encapsulation of three cannabis-based terpenes on their potential efficacy in pain management was published in the International Journal of Pharmaceutics on March 25. For...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.